



Curriculum Vitae

Personal information Vesna Višekruna Vucina

Work experience

Feb 2019 - present: Head of Department of Immunization, Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health

April 2014- present: Medical epidemiology specialist at Division for Epidemiology of communicable diseases, Croatian Institute of Public Health

2009-2011: General practice doctor, Health Center Vrbovec, Croatia

2008-2009: Medical Doctor, internship at Clinical Hospital "Sveti Duh", Zagreb, Croatia

Education and training

2020 -present: PhD student a Faculty of Medicine, University of Rijeka, Croatia

2011-2014: specialization in epidemiology; Croatian Institute of Public Health, Croatia

2013: postgraduate university specialist studies in epidemiology, School of Medicine, University of Zagreb, Croatia

2008: Croatian State Exam in Medicine

2001-2007: School of Medicine, University of Zagreb, Croatia

Additional information

Publications

1. V.Višekruna Vučina, S.Kurečić Filipović, N.Kožnjak, V.Stamenić, A.D.Clark, B.Mounaud, J.Blau, C.Hoestlandt, B.Kaić Cost-effectiveness of pneumococcal conjugate vaccination in Croatia, *Vaccine*. 2015 May 7;33 Suppl 1:A209-A218. doi: 10.1016/j.vaccine.2014.12.043. <http://www.sciencedirect.com/science/article/pii/S0264410X1401696X>
2. Kaić B, Tomić B, Nemeth-Blažić T, Kurečić Filipović S, Višekruna Vučina V, Draženović V, Pem Novosel I, Šimunović A, Gjenero-Margan I. Guillain Barré sindrom i cijepljenje protiv gripe HČJZ 2013; 9(33):224-231. 3. Pem Novosel I, Sanja Kurečić Filipović, Ira Gjenero Margan, Bernard Kaić, Marijan Erceg, Vesna Višekruna Vučina: Epidemiologija krpeljnog meningoencefalitisa u Hrvatskoj, 1993.- 2012. godine / *Epidemiology of tick-borne encephalitis in Croatia, 1993 – 2012 CROCMID2013*, Rovinj 24.-27. listopada 2013 Kurečić-Filipović S, Gjenero-Margan I, Kaić B, Kolarić B, Pem-Novosel I, Višekruna-Vučina V. Djelotvornost cjepiva protiv parotitisa, soj L-Zagreb, u uvjetima niske cirkulacije prirodnog soja virusa mumpsu a populaciji. 3.Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 104. 4.Višekruna-Vučina V, Gjenero-Margan I, Kurečić-Filipović S, Pem-Novosel I, Kaić B. Dob primjene kombiniranih cjepiva koja sadrže acelularnu pertusis komponentu i obuhvati prijavljivanja nuspojava u Hrvatskoj 2008-2010. 3. Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 125. 5. Pem-Novosel I, Vilibić-Cavlek T, Gjenero-Margan I, Kurečić-Filipović, Aleraj B, Babić-Erceg A, Klobučar A,, Kaić B, Miletić-Medved, Jeličić P, Višekruna-Vučina V, Erceg M. Istraživanje prevalencije denge infekcije u Hrvatskoj. 3.Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 113. 6. T. Nemeth Blažić, Z. Dominiković, M.L.Kosanović Ličina, V. Višekruna Vučina, L. Kasumović, J. Pavlič Akcija testiranja na HIV u LGBT centru Zagreb (MSM) tijekom europskog tjedna testiranja na HIV 2014. 3.Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 110. 7. European Centre for Disease Prevention and Control. Vaccine hesitancy among healthcare workers and their patients in Europe -A qualitative study. Stockholm: ECDC; 2015 (coauthor) <http://ecdc.europa.eu/en/publications/Publications/vaccine-hesitancy-among-healthcare-workers.pdf>
- 8.Višekruna Vučina V, Kaić B. Registar nuspojava cijepljenja u Hrvatskom zavodu za javno zdravstvo, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 31-38 str. 9. Kaić B, Višekruna Vučina V. Program obveznog cijepljenja u Republici Hrvatskoj, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 1-9 str. 10. Kaić B, Višekruna Vučina V. Protokol nadoknadnog cijepljenja, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 268-280 str. 11. M Rondy, A Larrauri, I Casado, V Alfonsi, D Pitigoi, O Launay, RK Syrjänen, G Gefenaite, A Machado, VV Vučina, JK Horváth, I Paradowska-Stankiewicz, SD Marbus, A Gherasim, JA Díaz-González, C Rizzo, AE Ivanciuc, F Galtier, N Ikonen, A Mickiene, V Gomez, S Kurečić Filipović, A Ferenczi, MR Korcinska, R van GageldonkLafeber, I-MOVE+ hospital working group, M Valenciano Research article: 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project; *Eurosurveillance*, Volume 22, Issue 30, 27 July 2017. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22842>
12. E.Kissling, M.Rondy, I-MOVE/I-MOVE+ study team Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.7.30464>
13. M.Rondy, O.Launay, J.Castilla, S.Costanzo, JP. Barberà, G. Gefenaite; A. Larrauri; C.Rizzo; D. Pitigoi; R.K. Syrjänen InNHOVE and IMOVE+ working group Repeated seasonal influenza vaccination among elderly in Europe:Effects on laboratory confirmed hospitalised influenza <https://www.sciencedirect.com/science/article/pii/S0264410X17308964?via%3Dihub>
14. M.Rondy, E. Kissling, HD Emborg, A. Gherasim, R. Pebody, R. Trebbien, F.Pozo, A.Larrauri, J.McMenamin, M.Valenciano, I-MOVE/I-MOVE+ group Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies <https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/23/9/eurosurv-23-9->

1.pdf?expires=1538738850&id=id&accname=guest&checksum=EBF1E9AF779EC8A67181CF366CF4B1EE 15. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 <http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089> 16. Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study <http://dx.doi.org/10.1111/irv.13243> 17. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I - MOVE primary care multicentre study <http://dx.doi.org/10.1111/irv.13069> 18.

Projects

2022 - ongoing Vebis Lot 5; ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection among patients presenting to primary care physicians

2015-2022 IMOVE project; Integrated Monitoring of Vaccines in Europe; Monitoring influenza vaccine effectiveness (seasonal and pandemic) in EU/EEA

Memberships

Other Relevant Information